ESCALATE trial, a phase 3 randomized EORTC study comparing intermittent against continuous ADT plus ARPI-based therapy in metastatic hormone-sensitive ...
Aishwarya Atmakuri describes a multiplex immunofluorescence analysis of 29 radical prostatectomy specimens from treatment-naive patients comparing the immune microenvironment of l ...
Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...
Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...
Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...
Jianpeng Yu discusses single-center data on urinary tumor DNA as a guide for deescalating systemic immunotherapy in very high-risk non-muscle-invasive bladder cancer. All enrolled patients had ...
Daniel Petrylak shares interim results from Duravelo-2, a study of zelenectide in patients with one prior line of therapy for metastatic urothelial carcinoma. Zelenectide is a bicyclic peptide ...
Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer - Beyond the Abstract ...
Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson PIVOT-006 Trial: Cretostimogene Grenadenorepvec for Intermediate-Risk Non-Muscle Invasive Bladder ...
Bladder preservation has emerged as an established treatment option for selected patients with muscle-invasive bladder cancer (MIBC), offering durable oncologic control with the potential to maintain ...
Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results